Skip to main content
logo
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.75
+0.11 (1.44%)
Aug 6, 2026, 4:00 PM EDT - Market closed

Kyverna Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----7.035.66
Revenue Growth
----24.20%-
Gross Profit
----7.035.66
Operating Income
-163.79-169.83-142.6-62.41-29.38-26.35
Net Income
-156.4-161.31-127.48-60.37-28.89-26.35
Earnings Per Share
-3.28-3.64-3.33-89.61-63.43-99.10
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
236.45279.25285.9857.5451.3276.07
Total Debt
33.7629.038.249.0810.565.56
Net Cash (Debt)
202.69250.22277.7448.4640.7670.51
Net Cash Growth
-14.01%-9.91%473.08%18.91%-42.20%-
Net Cash Per Share
4.175.657.2571.9589.480.27

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-150.39-153.71-114.25-52.41-36.11-22.16
Capital Expenditures
--0.01-2.21-0.62-0.77-1.29
Free Cash Flow
-150.39-153.72-116.46-53.03-36.88-23.44
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----100.00%100.00%
Operating Margin
-----418.28%-465.81%
Pretax Margin
-----411.29%-465.88%
Profit Margin
-----411.29%-465.88%
FCF Margin
-----525.00%-414.50%

Valuation
Selected indicators aren't available for this stock.